Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients

Table 4 Comparison of biomarker profiles before and after NAC

	Before NAC							After NAC							Test	n	p-value
HER2	0	1	2			3		0	1			2		3	Chi-square	143	0.072
HER2	11	37	61			34		3	51			57		32	Chi-square	143	0.072
ER	Mean = 52.42							Mean = 49.36							Wilcoxon	146	0.039*
ER	-		+					-				+			Chi-square	146	0.58
ER	32		114					36				110			Chi-square	146	0.58
PR	Mean = 31.45							Mean = 22.28							Wilcoxon	146	0.013*
PR	-			+				-		+					Chi-square	146	0.52
PR	41			105				46		100					Chi-square	146	0.52
TOPO II	0	1		2	3		4	0	1	2	3		4		Chi-square	84	0.041*
TOPO II	1	43		35	5		0	4	53	18	8		1		Chi-square	84	0.041*
EGFR	-	+		++	+++			-	+	++	+++				Chi-square	88	0.73
EGFR	45	31		9	3			47	29	11	1				Chi-square	88	0.73
Ki67	Mean = 35.28							Mean = 27.18							Wilcoxon	145	<0.001*
CK5/6	-			+				-		+					Chi-square	86	0.22
CK5/6	68			18				61		25					Chi-square	86	0.22
AR	Mean = 33.30							Mean = 29.67							Wilcoxon	99	0.22
p53	Mean = 25.32							Mean = 25.68							Wilcoxon	87	0.93

n is the number of patients having paired information (both before and after NAC) therefore used for the according analysis
*differences are considered statistically significant at a p-value of less than 0.05

ISSN: 1746-1596